"/>
欧美精品在线第一页,久久av影院,午夜视频在线播放一三,久久91精品久久久久久秒播,成人一区三区,久久综合狠狠综合久久狠狠色综合,成人av一区二区亚洲精,欧美a级在线观看

FDA approves two drugs combined to treat aggressive thyroid cancer

Source: Xinhua    2018-05-05 03:21:12

WASHINGTON, May 4 (Xinhua) -- The U.S. Food and Drug Administration (FDA) approved on Friday new uses for two drugs administered together for the treatment of a kind of anaplastic thyroid cancer (ATC).

Tafinlar (dabrafenib) and Mekinist (trametinib) in combination have been greenlighted to treat ATC that cannot be removed by surgery or has spread to other parts of the body and has a type of abnormal gene called BRAF V600E.

"This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.

"This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients."

Both drugs have been approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma.

Also, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland.

Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer, accounting for about 1 to two percent of all thyroid cancers.

The trial measured the percent of patients with a complete or partial reduction in tumor size, according to FDA.

Of 23 evaluable patients, 57 percent experienced a partial response and four percent experienced a complete response.

In nine (64 percent) of the 14 patients with responses, there were no significant tumor growths for six months or longer.

Both Tafinlar and Mekinist can cause harm to a developing fetus, so women should be advised of the potential risk to the fetus and to use effective contraception, FDA warned.

Editor: Chengcheng
Related News
Xinhuanet

FDA approves two drugs combined to treat aggressive thyroid cancer

Source: Xinhua 2018-05-05 03:21:12

WASHINGTON, May 4 (Xinhua) -- The U.S. Food and Drug Administration (FDA) approved on Friday new uses for two drugs administered together for the treatment of a kind of anaplastic thyroid cancer (ATC).

Tafinlar (dabrafenib) and Mekinist (trametinib) in combination have been greenlighted to treat ATC that cannot be removed by surgery or has spread to other parts of the body and has a type of abnormal gene called BRAF V600E.

"This is the first FDA-approved treatment for patients with this aggressive form of thyroid cancer, and the third cancer with this specific gene mutation that this drug combination has been approved to treat," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.

"This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients."

Both drugs have been approved for use, alone or in combination, to treat BRAF V600 mutation-positive metastatic melanoma.

Also, Tafinlar and Mekinist are approved for use, in combination, to treat BRAF V600E mutation-positive, metastatic non-small cell lung cancer.

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid gland.

Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer, accounting for about 1 to two percent of all thyroid cancers.

The trial measured the percent of patients with a complete or partial reduction in tumor size, according to FDA.

Of 23 evaluable patients, 57 percent experienced a partial response and four percent experienced a complete response.

In nine (64 percent) of the 14 patients with responses, there were no significant tumor growths for six months or longer.

Both Tafinlar and Mekinist can cause harm to a developing fetus, so women should be advised of the potential risk to the fetus and to use effective contraception, FDA warned.

[Editor: huaxia]
010020070750000000000000011100001371567761
主站蜘蛛池模板: 日本五十熟hd丰满| 日本一区欧美| 国产一区二区在线观| 国产精品伦一区二区三区级视频频 | 亚洲精品久久久久久久久久久久久久 | 欧美在线观看视频一区二区 | 国产jizz18女人高潮| 国产91色综合| 91福利视频导航| 久久99视频免费| 国产一区观看| 久久99中文字幕| 国产区二区| 99视频国产在线| 久久精品一区二区三区电影| 久久久精品欧美一区二区| 国产精品视频免费一区二区| 免费看片一区二区三区| 欧美freesex极品少妇| 在线国产精品一区二区| 国产一区二区伦理片| 首页亚洲欧美制服丝腿 | 日韩av在线影院| 91久久香蕉| 99国产精品一区| 性视频一区二区三区| 精品国产免费一区二区三区| 93精品国产乱码久久久| 99热久久这里只精品国产www | 国产麻豆一区二区| 午夜激情电影在线播放| 99爱精品视频| 久久99精品一区二区三区| 欧美在线观看视频一区二区三区| 国产一区二区在线精品| 强制中出し~大桥未久10| 精品国产乱码久久久久久久久 | 国产在线一区观看| 清纯唯美经典一区二区| 欧美一区二区三区久久精品视| 国产一区二区午夜| 一区二区三区国产欧美| 国产精品第157页| 国产高清不卡一区| 91精品久久久久久| 日韩国产精品一区二区| 国产欧美日韩精品一区二区三区| 国产高清无套内谢免费| 国产精品欧美一区乱破| 日韩av在线中文| 99久久精品免费看国产免费粉嫩| 亚洲自拍偷拍一区二区三区| 狠狠色噜噜狠狠狠狠米奇777| 国产高清在线一区| 玖玖玖国产精品| 51区亚洲精品一区二区三区| 久久午夜鲁丝片| 久久久久亚洲精品视频| 97人人模人人爽人人喊小说| 狠狠色丁香久久婷婷综| 色就是色欧美亚洲| 93久久精品日日躁夜夜躁欧美| 国产高清精品一区| 国产精品久久国产三级国电话系列| 久久一区二区三区视频| 国产欧美一区二区三区免费视频 | 88888888国产一区二区| 视频一区欧美| 久久不卡一区| 国产69久久| 国产一二区精品| 午夜特片网| 中文字幕日韩一区二区| 日本99精品| 少妇又紧又色又爽又刺激的视频 | 欧美高清性xxxxhd| 国产88在线观看入口| 最新国产精品自拍| 国产精品午夜一区二区三区视频| 国产亚洲欧美日韩电影网| 久久久久久久久亚洲精品| 在线国产精品一区|